Abbott designed the Volt PFA catheter for maneuverability, efficient ablation and thermal risk mitigation, said Dr.

Pulse Biosciences is developing nsPFA technology for cardiac ablation to treat AFib and for ablating benign thyroid nodules.

GAAP diluted EPS of $0.76; adjusted diluted EPS of $1.09 First-quarter reported sales growth of 4.0 percent; organic sales growth of 6.9 percent or ...

Guidance: Abbott reaffirms full-year 2025 adjusted EPS of $5.05-$5.25 versus a consensus of $5.15, with organic sales growth ...

The company recently announced that its Volt PFA System, designed to treat atrial fibrillation—a common heart condition—has received CE mark approval in Europe. The system uses pulsed field ...

Q1 2025 Earnings Conference Call April 16, 2025 9:00 AM ETCompany ParticipantsMike Comilla - VP, IRRobert Ford - Chairman ...

CEO Robert Ford noted that Abbott has 90 manufacturing locations worldwide, with plants close to customers, redundancy, and ...

We recently published a list of the 10 Best Dividend Monarchs to Invest in Now. In this article, we are going to take a look ...

Despite major product launches from diabetes rivals last year, Abbott’s diabetes unit brought in $1.8bn total Q1 sales to ...

In March, Abbott received CE Mark for the Volt PFA System to treat patients battling atrial fibrillation (AFib). This device is aimed to cater to 8 million Europeans over the age of 65 living with ...

Q1 2025 Management View CEO Robert Ford highlighted the robust performance for Q1 2025, with high single-digit sales growth and double-digit earnings per share (EPS) growth. Adjusted EPS for the ...